Clinical Trial

Problem Management Plus Mindfulness-informed Legal Education for Addressing Gender-based Violence and Improving Parenting

Study acronym: PM+MiLE
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Gender-based violence and, more specifically, domestic violence is a prevalent problem globally and in Nigeria. Its effect significantly impacts women and also the wellbeing of their families. Limited access to support has posed a constraint in effectively addressing the issues suffered by affected victims in Nigeria. In addition, gender-based violence could affect parenting due to factors such as anxiety, trauma, depression, poor social support, limited awareness of legal channels for complaint and harsh parenting to children. The implication is that it could not only have a negative impact on the affected victim but also on their parenting styles or caring responsibilities, which could be detrimental to the child development, wellbeing and the potential subsequent resort to criminal behaviours. In essence, the current study aims to test the feasibility and acceptability of a novel cross disciplinary intervention titled, Problem Management plus Mindfulness-informed Legal Education (PM+MiLE) for addressing gender-based violence and improving parenting in Nigeria in comparison to the waitlist control group for the purposes of improving social cohesion, legal awareness, wellbeing and reducing depression, including trauma and anxiety as a result of experiencing gender-based violence, in Nigeria.
Trial Details
NCT Number NCT06601023
Lead Sponsor Teesside University
Collaborators: Jos University Teaching Hospital, University of Manchester
Conditions Depression, Anxiety, Trauma, Anxiety, Parenting Intervention, Woman Abuse, Child Behaviour, Stress
Enrollment 24 participants
Start Date 2024-09-24
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19